Tech Company Financing Transactions

Relay Therapeutics Funding Round

Relay Therapeutics, based in Cambridge, secured $400 million from SoftBank Vision Fund, Alexandria Venture Investments and BVF Partners.

Transaction Overview

Company Name
Relay Therapeutics
Announced On
12/21/2018
Transaction Type
Venture Equity
Amount
$400,000,000
Round
Series C
Investors

SoftBank Vision Fund (Lead Investor) (Deep Nishar)

Alexandria Venture Investments

BVF Partners (Kanishka Pothula)

Casdin Capital

D. E. Shaw Group (David Shaw)

EcoR1 Capital Management

Foresite Capital

GV (Krishna Yeshwant)

Perceptive Advisors

Tavistock Life Sciences

Proceeds Purpose
Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics' long-term strategy.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St. 3rd Floor
Cambridge, MA 02142
USA
Phone
(617) 370-8837
Website
www.relaytx.com
Email Address
[email protected]
Overview
Relay Therapeutics (Nasdaq: RLAY) is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion.
Profile
Relay Therapeutics LinkedIn Company Profile
Social Media
Relay Therapeutics Company Twitter Account
Company News
Relay Therapeutics News
Facebook
Relay Therapeutics on Facebook
YouTube
Relay Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Sanjiv Patel
  Sanjiv Patel LinkedIn Profile  Sanjiv Patel Twitter Account  Sanjiv Patel News  Sanjiv Patel on Facebook
Vice President
Pascal Fortin
  Pascal Fortin LinkedIn Profile  Pascal Fortin Twitter Account  Pascal Fortin News  Pascal Fortin on Facebook
Vice President
Patrick Walters
  Patrick Walters LinkedIn Profile  Patrick Walters Twitter Account  Patrick Walters News  Patrick Walters on Facebook
Vice President
James Watters
  James Watters LinkedIn Profile  James Watters Twitter Account  James Watters News  James Watters on Facebook
VP - Finance
Thomas Catinazzo
  Thomas Catinazzo LinkedIn Profile  Thomas Catinazzo Twitter Account  Thomas Catinazzo News  Thomas Catinazzo on Facebook
VP - General Counsel
Brian Adams
  Brian Adams LinkedIn Profile  Brian Adams Twitter Account  Brian Adams News  Brian Adams on Facebook
VP - Human Resources
Sarah O'Brien
  Sarah O'Brien LinkedIn Profile  Sarah O'Brien Twitter Account  Sarah O'Brien News  Sarah O'Brien on Facebook
VP - R & D
Donald Bergstrom
  Donald Bergstrom LinkedIn Profile  Donald Bergstrom Twitter Account  Donald Bergstrom News  Donald Bergstrom on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/21/2018: M3 Biotechnology venture capital transaction
Next: 12/21/2018: ACV Auctions venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.